p53 mutations have been reported in >80% of triple-negative breast cancers.25 Most of the mutations are localized to the DNA binding domain, perturbing the affinity of p53 for the promoter and altering the expression of transcriptional target genes.26 We noticed that HCC1569, a p53-null cell line, shows high levels of RP11-1911.1, and therefore we asked whether the knock-down of the lncRNA could induce the same response in p53 target genes. This evidence concerns the gene TP53 and triple-negative breast carcinoma.